ARGENX SE EO -,10/ NL0010832176 /
2024-09-10 6:43:22 PM | Chg. -14.200 | Volume | Bid2024-09-10 | Ask2024-09-10 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
484.500EUR | -2.85% | 44 Turnover: 21,318 |
478.100Bid Size: 41 | 489.100Ask Size: 41 | 28.89 bill.EUR | - | - |
GlobeNewswire
08-26
MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire
08-12
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire
07-25
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire
07-18
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...
GlobeNewswire
07-16
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...
GlobeNewswire
06-25
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
06-21
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire
06-17
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire
06-13
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire
05-09
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-02
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire
04-16
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire
03-27
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire
03-26
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire
03-07
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire
02-29
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update